Lauren Rice

Dr. Lauren Rice

Faculty of Medicine & Health, The University of Sydney, Sydney, New South Wales, Australia
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2014 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
SEStewart L. Einfeld
Stewart L. Einfeld
ESEllie Smith
Ellie Smith
IMIain S. McGregor
Iain S. McGregor
KSKate Steinbeck
Kate Steinbeck
JTJohn Taffe
John Taffe
AGAdam J. Guastella
Adam J. Guastella

21 June 2021 in Journal of Neurodevelopmental Disorders
Verified
Journal Article
Open access
PDF file
LSLauren Schwartz
Lauren Schwartz
ACAssumpta Caixàs
Assumpta Caixàs
ADAnastasia Dimitropoulos
Anastasia Dimitropoulos
EDElisabeth Dykens
Elisabeth Dykens
JDJessica Duis
Jessica Duis
KWKate Woodcock
Kate Woodcock
Prader-Willi syndrome (PWS) is a rare neurodevelopmental genetic disorder associated with a characteristic behavioral phenotype that includes severe hyperphagia and a variety of other behavioral challenges such as temper outbursts and anxiety. These behaviors have a significant and dramatic impact on the daily functioning and quality of life for the person with PWS and their families. To date, effective therapies addressing these behavioral challenges have proven elusive, but several potential treatments are on the horizon. However, a limiting factor for treatment studies in PWS is the lack of consensus in the field regarding how to best define and measure the complex and interrelated behavioral features of this syndrome. The International PWS Clinical Trials Consortium (PWS-CTC, www.pwsctc.org) includes expert PWS scientists, clinicians, and patient advocacy organization representatives focused on facilitating clinical trials in this rare disease. To address the above gap in the field, members of the PWS-CTC “Behavior Outcomes Working Group” sought to develop a unified understanding of the key behavioral features in PWS and build a consensus regarding their definition and description. The primary focus of this paper is to present consensus definitions and descriptions of key phenotypic PWS behaviors including hyperphagia, temper outbursts, anxiety, obsessive–compulsive behaviors, rigidity, and social cognition deficits. Patient vignettes are provided to illustrate the interrelatedness and impact of these behaviors. We also review some available assessment tools as well as new instruments in development which may be useful in measuring these behavioral features in PWS.

1 March 2018 in Current Opinion in Psychiatry
Verified
Journal Article
Closed access
PDF file
LRLauren Rice
Lauren Rice
SEStewart L. Einfeld
Stewart L. Einfeld
NHNan Hu
Nan Hu
CCC. Sue Carter
C. Sue Carter
PWS is a severe developmental disability for which there is no known treatment. The oxytocin system is currently a primary target for intervention. The aim of this article is to review the evidence for the efficacy of intranasal oxytocin in PWS. To date, there have been five clinical trials of oxytocin in PWS. Four of these studies reported that oxytocin improved behaviors. However, each of these studies suffered important limitations that likely influenced the findings. For example, one study did not include a control group. Another study did not statistically analyze the effects of oxytocin on behavior. The final two studies used study-specific measures for which psychometric properties have not been assessed. Because of these limitations, the most appropriate conclusion to draw from the existing studies is that there is currently no convincing evidence that intranasal oxytocin improves symptoms of PWS. However, this does not mean that oxytocin is not involved in PWS. Rather, it suggests that further work is needed to understand the nature of the PWS oxytocin abnormality.

1 March 2015 in Current Opinion in Psychiatry
Verified
Journal Article
Closed access
LRLauren Rice
Lauren Rice
SEStewart L. Einfeld
Stewart L. Einfeld
To provide a review of the recent advances in the diagnosis and treatment of psychiatric disorders in Prader-Willi syndrome (PWS). Research in the last 12 months has provided a descriptive prognosis of psychosis in PWS and highlighted the possible genes associated with the increased risk of psychosis for those with maternal uniparental disomy (mUPD). Several studies investigating social and communication skills have shown people with PWS to have difficulty with core, receptive and expressive language skills, interpreting emotional valence in faces, playing with children of their own age, understanding personal space and a developmental delay in the theory of mind. These social and communication deficits are often more pronounced in those with mUPD. Two recent clinical trials of oxytocin provide mixed results and highlight the need for an improved understanding of the neurobiological characteristics of the PWS brain. A recent pilot study suggests N-acetylcysteine may be a viable treatment for skin picking. Recent advances have contributed to our understanding of the emotional and behavioural problems associated with PWS, and provided directions for further research.

5 October 2018 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
LRLauren Rice
Lauren Rice
KWKate Woodcock
Kate Woodcock
SEStewart L. Einfeld
Stewart L. Einfeld

15 May 2015 in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
Verified
Journal Article
Closed access
PDF file
LRLauren Rice
Lauren Rice
KGKylie M. Gray
Kylie M. Gray
PHPatricia Howlin
Patricia Howlin
JTJohn Taffe
John Taffe
BTBruce J. Tonge
Bruce J. Tonge
SEStewart L. Einfeld
Stewart L. Einfeld